28 Aug 2026
We are pleased to share that NICE has recognised another clinical guideline published as part of the Duchenne Care UK national programme that we fund. NICE (the National Institute for Health and Care Excellence) has reviewed Duchenne Care UK’s recommendations on...
8 May 2026
On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...
12 Jan 2026
The Duchenne Research Fund is delighted to share that NICE has recognised the respiratory care guidelines that were created and published by the DMD Care UK programme that we fund. This follows NICE’s recognition of DMD Care UK’s cardiac guidelines in...
9 Dec 2025
Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk at the start of treatment. Givinostat (also known by its brand name Duvyzat) was approved for market authorisation...
7 Sep 2025
On World Duchenne Awareness Day 2025, the Duchenne Research Fund is delighted to share that NICE has recognised the cardiac care guidelines that were created and published by the DMD Care UK programme that we fund. As stated on NICE’s website: “We think...
15 Aug 2025
The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...
10 Dec 2024
New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...
18 Dec 2023
The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...
13 Oct 2023
We are pleased to share that the EMA (European Medicines Agency) has recommended the approval of Vamorolone – the first ever treatment for all patients with Duchenne. Vamorolone is an alternative to corticosteroids. It was developed with the aim of maximising...